JP2019501216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501216A5 JP2019501216A5 JP2018547255A JP2018547255A JP2019501216A5 JP 2019501216 A5 JP2019501216 A5 JP 2019501216A5 JP 2018547255 A JP2018547255 A JP 2018547255A JP 2018547255 A JP2018547255 A JP 2018547255A JP 2019501216 A5 JP2019501216 A5 JP 2019501216A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- weight
- pharmaceutical composition
- dosage form
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002270 dispersing agent Substances 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 43
- 229920000642 polymer Polymers 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 11
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000007962 solid dispersion Substances 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 5
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 208000015658 resistant hypertension Diseases 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- CYSJNTQNMDWAJV-UHFFFAOYSA-N praliciguat Chemical compound C1=C(F)C(NCC(O)(C(F)(F)F)C(F)(F)F)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 CYSJNTQNMDWAJV-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 4
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021157646A JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260910P | 2015-11-30 | 2015-11-30 | |
| US62/260,910 | 2015-11-30 | ||
| US201662359440P | 2016-07-07 | 2016-07-07 | |
| US62/359,440 | 2016-07-07 | ||
| PCT/US2016/063312 WO2017095697A1 (en) | 2015-11-30 | 2016-11-22 | Solid dispersions comprising a sgc stimulator |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021157646A Division JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501216A JP2019501216A (ja) | 2019-01-17 |
| JP2019501216A5 true JP2019501216A5 (enExample) | 2020-01-09 |
| JP6952707B2 JP6952707B2 (ja) | 2021-10-20 |
Family
ID=57590822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547255A Active JP6952707B2 (ja) | 2015-11-30 | 2016-11-22 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
| JP2021157646A Active JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
| JP2023076655A Active JP7641320B2 (ja) | 2015-11-30 | 2023-05-08 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021157646A Active JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
| JP2023076655A Active JP7641320B2 (ja) | 2015-11-30 | 2023-05-08 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20190269619A1 (enExample) |
| EP (1) | EP3383372B1 (enExample) |
| JP (3) | JP6952707B2 (enExample) |
| KR (1) | KR102841419B1 (enExample) |
| CN (4) | CN116637077A (enExample) |
| AU (1) | AU2016364976B2 (enExample) |
| BR (1) | BR112018011154B1 (enExample) |
| CA (1) | CA3006746C (enExample) |
| EA (1) | EA201891315A1 (enExample) |
| IL (2) | IL259493B (enExample) |
| MX (3) | MX389961B (enExample) |
| WO (1) | WO2017095697A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11357777B2 (en) | 2016-02-01 | 2022-06-14 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) |
| EA201990236A1 (ru) | 2016-07-07 | 2019-08-30 | Сайклерион Терапьютикс, Инк. | Новые способы получения стимуляторов растворимой гуанилатциклазы |
| KR102487872B1 (ko) * | 2016-07-07 | 2023-01-12 | 사이클리온 테라퓨틱스, 인크. | 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법 |
| WO2019055859A1 (en) | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| CN111902410B (zh) * | 2018-01-10 | 2024-04-19 | 赛克里翁治疗有限公司 | 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物 |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| WO2019172420A1 (ja) * | 2018-03-09 | 2019-09-12 | 協和発酵キリン株式会社 | 医薬組成物 |
| EP3829644A4 (en) * | 2018-07-30 | 2022-05-04 | Ricoh Company, Ltd. | PROCESS FOR MANUFACTURING PARTICLES AND PARTICLE AND MEDICATION MANUFACTURED BY THE PROCESS |
| JP7503781B2 (ja) * | 2018-07-30 | 2024-06-21 | 株式会社リコー | 粒子の製造方法、並びに、それにより製造された粒子及び医薬 |
| JP7634525B2 (ja) * | 2019-09-23 | 2025-02-21 | バイオノミクス リミテッド | 治療用製剤およびその使用 |
| CN115175683A (zh) | 2019-10-29 | 2022-10-11 | 赛克里翁治疗有限公司 | 用sGC刺激剂治疗糖尿病性肾病 |
| CN116685308A (zh) * | 2020-12-18 | 2023-09-01 | Ucb生物制药有限责任公司 | 无定形固体分散体 |
| EP4376843A1 (en) | 2021-07-28 | 2024-06-05 | Cyclerion Therapeutics, Inc. | Treatment of hfpef in post-menopausal women with an sgc stimulator |
| WO2026035689A1 (en) * | 2024-08-06 | 2026-02-12 | Catalyst Pharmaceuticals, Inc. | Vamorolone solid oral dosage forms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
| WO2012122279A1 (en) * | 2011-03-08 | 2012-09-13 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| CA2861804C (en) * | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators |
| WO2014047111A1 (en) * | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| ES2911276T3 (es) * | 2013-03-15 | 2022-05-18 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| WO2015106268A1 (en) * | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| EP3194382B1 (en) * | 2014-09-17 | 2021-09-08 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sgc stimulators |
-
2016
- 2016-11-22 BR BR112018011154-6A patent/BR112018011154B1/pt active IP Right Grant
- 2016-11-22 AU AU2016364976A patent/AU2016364976B2/en active Active
- 2016-11-22 JP JP2018547255A patent/JP6952707B2/ja active Active
- 2016-11-22 US US15/780,212 patent/US20190269619A1/en not_active Abandoned
- 2016-11-22 CN CN202310714725.6A patent/CN116637077A/zh active Pending
- 2016-11-22 EA EA201891315A patent/EA201891315A1/ru unknown
- 2016-11-22 EP EP16816486.1A patent/EP3383372B1/en active Active
- 2016-11-22 KR KR1020187018204A patent/KR102841419B1/ko active Active
- 2016-11-22 WO PCT/US2016/063312 patent/WO2017095697A1/en not_active Ceased
- 2016-11-22 MX MX2018006422A patent/MX389961B/es unknown
- 2016-11-22 CN CN202310714716.7A patent/CN116637076A/zh active Pending
- 2016-11-22 CA CA3006746A patent/CA3006746C/en active Active
- 2016-11-22 CN CN201680077389.7A patent/CN108883071A/zh active Pending
- 2016-11-22 CN CN202310714714.8A patent/CN116942616A/zh active Pending
-
2018
- 2018-05-21 IL IL259493A patent/IL259493B/en unknown
- 2018-05-24 MX MX2022001655A patent/MX2022001655A/es unknown
- 2018-05-24 MX MX2022001656A patent/MX2022001656A/es unknown
-
2021
- 2021-09-28 JP JP2021157646A patent/JP7277534B2/ja active Active
-
2022
- 2022-02-03 IL IL290338A patent/IL290338B2/en unknown
-
2023
- 2023-05-08 JP JP2023076655A patent/JP7641320B2/ja active Active
- 2023-12-29 US US18/400,392 patent/US20240293324A1/en not_active Abandoned
-
2024
- 2024-05-16 US US18/665,775 patent/US20250017862A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,072 patent/US20250255821A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12629369B2 (en) | Pharmaceutical compositions of nilotinib | |
| DK2579854T4 (en) | Solid compositions | |
| AU2012340759B2 (en) | Pharmaceutical formulations | |
| JP2015534973A (ja) | 抗レトロウイルス医薬組成物 | |
| US10874618B2 (en) | Compositions for treatment of heart failure in dogs | |
| CN101795673A (zh) | 增强的拉莫三嗪制剂 | |
| US20120264780A1 (en) | Solid compositions | |
| EP2994131A1 (en) | Low dose pharmaceutical composition | |
| US20140234415A1 (en) | Tablet Dosage Forms | |
| JP2017502062A5 (enExample) | ||
| CN105232489B (zh) | 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 | |
| WO2024189127A1 (en) | Compositions for sustained release of poorly soluble active ingredients | |
| JP6231959B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤 | |
| EP3210599B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| JP2022520170A (ja) | アファビシン製剤、その作製方法及びその使用 | |
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| WO2025003956A1 (en) | High drug loading formulations of encorafenib | |
| CN104487057A (zh) | 波生坦控释口服制剂 | |
| US20200054659A1 (en) | Extended release capecitabine capsules | |
| KR20120012485A (ko) | 버스트 약물 방출 조성물 | |
| Dandan et al. | Recent advances in taste-masking technologies of paediatric formulations | |
| HK40006330A (en) | Solid compositions | |
| WO2018142359A1 (en) | Composition comprising immediate release and extended release capecitabine | |
| WO2017025894A1 (en) | Extended release capecitabine tablets | |
| HK1184068B (en) | Solid compositions |